These results suggest that SIRT1 ISGylation is upregulated with a further increase in response to doxorubicin and thereby decreases p53 acetylation, with stronger effects than the p53 ISGylation-mediated increase in p53 acetylation, which leads to limitation of cancer cell sensitivity to doxorubicin. The gene discussed is TP53; the disease is cancer.